$BEAM Cashflow Statement | Understand Stock

$BEAM

$24.68 +$0.89 (3.72%) Live

$BEAM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Loss from equity method investment
Depreciation and amortization
Amortization of investment discount (premiums)
In-process research and development charge
Stock-based compensation expense
Amortization of operating lease right-of-use assets
Change in operating lease right-of-use assets
Change in fair value of derivative liabilities
Change in fair value of contingent consideration liabilities
Change in fair value of non-controlling equity investments
Realized loss (gain) on sale of marketable securities
Gain on sale of equity method investment
Other
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other long-term assets
Accounts payable
Accrued expenses and other liabilities
Operating lease liabilities
Collaboration receivable
Deferred revenue
Other long-term liabilities

Net cash provided by (used in) operating activities
Investing activities
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Proceeds from sale of marketable securities
Cash paid for acquisition, net
Proceeds from sale of equity method investment
Net cash acquired from Guide
Net cash provided by (used in) investing activities

Financing activities
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs
Proceeds from issuance of common shares, net of commissions
Proceeds from issuances of stock under ESPP
Payment of equity offering costs
Equipment financings, net
Proceeds from exercise of stock options
Proceeds from private stock issuance
Net cash provided by (used in) financing activities
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash-beginning of year
Cash, cash equivalents and restricted cash-end of year
Supplemental disclosure of cash flow information:
Cash paid for interest
Supplemental disclosure of noncash investing and financing activities:
Property and equipment additions in accounts payable and accrued expenses
Equity issuance costs in accounts payable and accrued expenses
Fair value of common stock issued to settle success payment liability
Operating lease liabilities arising from obtaining right-of-use assets
Contingent consideration liabilities assumed in acquisition
Fair value of equity instruments issued in connection with asset acquisition
Fair value of equity instruments issued in connection with acquisition
Non-cash contribution of intellectual property to Orbital Therapeutics Inc.

Comments